Moderna Stock Soared 14% as NIH Plans COVID-Style Push for Cancer Vaccines

Moderna Inc. (MRNA) shares rose 4.13% on October 14, 2026, driven by optimism around its mRNA cancer vaccine pipeline and inclusion in the Nasdaq-100 Index. The company reported $143M in revenue and a net loss of $782M for the latest quarter, with $5.1B in cash reserves. Analysts have adjusted price targets, with Bank of America raising its target to $200 and Morgan Stanley to $95, both maintaining cautious ratings. The next key catalyst is Moderna's Q3 2026 earnings report on November 6, 2026.

Moderna Inc. (MRNA) stock rose 4.22% on October 14, 2026, driven by positive mRNA pipeline data and inclusion in the Nasdaq-100 index. The company reported Q2 2026 revenue of $143M, a net loss of $782M, and has $5.14B in cash. The US NIH's cancer vaccine initiative and Moderna's oncology ambitions are key catalysts. Analysts have mixed price targets, with Bank of America at $200 and Morgan Stanley at $95.

Moderna and MSD announced successful Phase III trial results for a personalized mRNA cancer vaccine, showing reduced melanoma recurrence. Roche and BioNTech halted a Phase II trial for colorectal cancer. Moderna's shares surged 60%, MSD's rose 6%. Analysts discuss implications for Swiss pharma giants Roche and Novartis, focusing on trial differences and market potential. Challenges include manufacturing time and cost.

Health Canada is reviewing Moderna's mRNA flu vaccine, mFlusiva, which has been approved in the U.S. and shown 27% greater effectiveness than traditional vaccines. Clinical trials with over 40,000 adults aged 50+ found lower flu-like illness rates. Decision expected this year, with potential variations in availability and cost.

Moderna (MRNA) stock has surged 621% in the past year, despite declining sales and heavy reliance on COVID vaccines. The company's potential growth hinges on intismeran autogene, a cancer therapy in development with Merck, which has shown promise in a Phase 3 trial. Moderna is preparing for a potential launch, but the therapy is not yet on sale. The company's revenue was $2.2 billion in the last year, with COVID vaccines making up 93% of sales.

Moderna's stock rose 14% to a 52-week high of nearly $225, driven by its return to the Nasdaq-100 and news of a government-backed cancer vaccine initiative. The company reported a $782 million net loss in Q2, raising concerns about its financial health. Upcoming events, including detailed Phase 3 melanoma data and Q3 earnings, are critical for the stock's future trajectory. Analysts have mixed price targets, ranging from $95 to $200.